<?xml version='1.0' encoding='utf-8'?>
<document id="31104266"><sentence text="A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients."><entity charOffset="74-94" id="DDI-PubMed.31104266.s1.e0" text="Dabigatran Etexilate" /><entity charOffset="96-106" id="DDI-PubMed.31104266.s1.e1" text="Dabigatran" /><entity charOffset="111-133" id="DDI-PubMed.31104266.s1.e2" text="Dabigatran Glucuronide" /><pair ddi="false" e1="DDI-PubMed.31104266.s1.e0" e2="DDI-PubMed.31104266.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31104266.s1.e0" e2="DDI-PubMed.31104266.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31104266.s1.e0" e2="DDI-PubMed.31104266.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31104266.s1.e1" e2="DDI-PubMed.31104266.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31104266.s1.e1" e2="DDI-PubMed.31104266.s1.e2" /></sentence><sentence text="The thrombin inhibitor dabigatran is administered as the prodrug dabigatran etexilate, which is a substrate of esterases and P-glycoprotein (P-gp)"><entity charOffset="23-33" id="DDI-PubMed.31104266.s2.e0" text="dabigatran" /><entity charOffset="65-85" id="DDI-PubMed.31104266.s2.e1" text="dabigatran etexilate" /><pair ddi="false" e1="DDI-PubMed.31104266.s2.e0" e2="DDI-PubMed.31104266.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31104266.s2.e0" e2="DDI-PubMed.31104266.s2.e1" /></sentence><sentence text=" Dabigatran is eliminated via renal excretion but is also a substrate of uridine 5'-diphospho (UDP)-glucuronosyltransferases (UGTs)"><entity charOffset="1-11" id="DDI-PubMed.31104266.s3.e0" text="Dabigatran" /></sentence><sentence text=" The objective of this study was to build a physiologically based pharmacokinetic (PBPK) model comprising dabigatran etexilate, dabigatran, and dabigatran 1-O-acylglucuronide to describe the pharmacokinetics in healthy adults and renally impaired patients mechanistically"><entity charOffset="106-126" id="DDI-PubMed.31104266.s4.e0" text="dabigatran etexilate" /><entity charOffset="128-138" id="DDI-PubMed.31104266.s4.e1" text="dabigatran" /><entity charOffset="144-174" id="DDI-PubMed.31104266.s4.e2" text="dabigatran 1-O-acylglucuronide" /><pair ddi="false" e1="DDI-PubMed.31104266.s4.e0" e2="DDI-PubMed.31104266.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31104266.s4.e0" e2="DDI-PubMed.31104266.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31104266.s4.e0" e2="DDI-PubMed.31104266.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31104266.s4.e1" e2="DDI-PubMed.31104266.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31104266.s4.e1" e2="DDI-PubMed.31104266.s4.e2" /></sentence><sentence text="" /><sentence text="Model development and evaluation were carried out using (i) physicochemical and absorption, distribution, metabolism, and excretion (ADME) parameter values of all three analytes; (ii) concentration-time profiles from 13 studies of healthy and renally impaired individuals after varying doses (0" /><sentence text="1-300Â mg), intravenous (dabigatran) and oral (dabigatran etexilate) administration, and different formulations of dabigatran etexilate (capsule, solution); and (iii) drug-drug interaction studies of dabigatran with the P-gp perpetrators rifampin (inducer) and clarithromycin (inhibitor)"><entity charOffset="24-34" id="DDI-PubMed.31104266.s7.e0" text="dabigatran" /><entity charOffset="46-66" id="DDI-PubMed.31104266.s7.e1" text="dabigatran etexilate" /><entity charOffset="114-134" id="DDI-PubMed.31104266.s7.e2" text="dabigatran etexilate" /><entity charOffset="199-209" id="DDI-PubMed.31104266.s7.e3" text="dabigatran" /><entity charOffset="260-274" id="DDI-PubMed.31104266.s7.e4" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e0" e2="DDI-PubMed.31104266.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e0" e2="DDI-PubMed.31104266.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e0" e2="DDI-PubMed.31104266.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e0" e2="DDI-PubMed.31104266.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e0" e2="DDI-PubMed.31104266.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e1" e2="DDI-PubMed.31104266.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e1" e2="DDI-PubMed.31104266.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e1" e2="DDI-PubMed.31104266.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e1" e2="DDI-PubMed.31104266.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e2" e2="DDI-PubMed.31104266.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e2" e2="DDI-PubMed.31104266.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e2" e2="DDI-PubMed.31104266.s7.e4" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e3" e2="DDI-PubMed.31104266.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31104266.s7.e3" e2="DDI-PubMed.31104266.s7.e4" /></sentence><sentence text="" /><sentence text="A PBPK model of dabigatran was successfully developed"><entity charOffset="16-26" id="DDI-PubMed.31104266.s9.e0" text="dabigatran" /></sentence><sentence text=" The predicted area under the plasma concentration-time curve, trough concentration, and half-life values of the assessed clinical studies satisfied the two-fold acceptance criterion" /><sentence text=" Metabolic clearances of dabigatran etexilate and dabigatran were implemented using data on carboxylesterase 1/2 enzymes and UGT subtype 2B15"><entity charOffset="25-45" id="DDI-PubMed.31104266.s11.e0" text="dabigatran etexilate" /><entity charOffset="50-60" id="DDI-PubMed.31104266.s11.e1" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.31104266.s11.e0" e2="DDI-PubMed.31104266.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31104266.s11.e0" e2="DDI-PubMed.31104266.s11.e1" /></sentence><sentence text=" In severe renal impairment, the UGT2B15 metabolism and the P-gp transport in the model were reduced to 67% and 65% of the rates in healthy adults" /><sentence text="" /><sentence text="This is the first implementation of a PBPK model for dabigatran to distinguish between the prodrug, active moiety, and main active metabolite"><entity charOffset="53-63" id="DDI-PubMed.31104266.s14.e0" text="dabigatran" /></sentence><sentence text=" Following adjustment of the UGT2B15 metabolism and P-gp transport rates, the PBPK model accurately predicts the pharmacokinetics in renally impaired patients" /><sentence text="" /></document>